biobetter PD-L1 checkpoint inhibitor (Abeome)

N/A

Report date: 2025/01/26 17:39:23

Base Information

Drug Namebiobetter PD-L1 checkpoint inhibitor (Abeome)
Drug Alias NamePD-L1 targeting biobetter (Abeome)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAbeome Corp
China Registration ClassN/A

Develop Information

Active CompaniesAbeome Corp
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A